U.S., Feb. 8 -- ClinicalTrials.gov registry received information related to the study (NCT06815471) titled 'CRF2 Agonist for the Treatment of Worsening Heart Failure' on Feb. 03.
Brief Summary: This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
Study Start Date: June, 2025
Study Type: INTERVENTIONAL
Condition:
Worsening Heart Failure
Intervention:
DRUG: CRF2 agonist
28-day treatment
DRUG: Placebo
28-day treatment
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Corteria Pharmaceuticals
Disclaimer: Curated by HT Syndication....